A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Jiangsu Provincial Center for Disease Control and Prevention

Status and phase: Completed; Phase 3

Conditions: Influenza

Treatments: Biological: Trivalent influenza vaccine A; Biological: Quadrivalent influenza vaccine; Biological: Trivalent influenza vaccine B

Study type: Interventional

Funder types: NETWORK; Industry

Identifiers

NCT02710409

JSVCT031

Details and patient eligibility

About

Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality.

In order to evaluate safety and immunogenicity of a quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase III clinical trial is planned to conduct in healthy Chinese subjects aged 3 years and older.

Full description

Subjects will be randomized into three arms- Experimental Group, Active Comparator A and Active Comparator B by the ratio of 2:1:1.

Enrollment: 3,664 patients

Sex: All

Ages: 3+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged 3 years and older
• Healthy subjects judged from medical history and clinical examination
• Subjects themselves or their guardians able to understand and sign the informed consent
• Subjects themselves or their guardians can and will comply with the requirements of the protocol
• Subjects with temperature <=37.0°C on axillary setting

Exclusion criteria

• Subject who has a medical or family history of any of the following: allergic history, seizure, epilepsy, brain or mental disease
• Any prior administration of influenza vaccine in last 6 month
• Subject who is allergic to any ingredient of the vaccine
• Female subject aged ≥18 years with a positive result after urine pregnancy test or during pregnancy or baby nursing period
• Subject with damaged or low immune function which has already been known
• Subject who had a seasonal influenza medical history in last 6 months
• Subject with acute febrile illness or infectious disease
• Major congenital defects or serious chronic illness, including perinatal brain damage
• Thrombocytopenia, blood coagulation disorder or bleeding difficulties with intramuscular injection
• Subject who has serious allergic history
• Subject with other medical history not suitable for vaccination such as fainting during injection
• Any prior administration of immunodepressant or corticosteroids in last 6 months
• Any prior administration of blood products in last 3 months
• Any prior administration of other research medicine/vaccine in last 30 days
• Any prior administration of any attenuated live vaccine in last 30 days
• Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine
• Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

3,664 participants in 3 patient groups

Quadrivalent influenza vaccine

Experimental group

Treatment:

Biological: Quadrivalent influenza vaccine

Trivalent influenza vaccine A

Active Comparator group

Description:

Active Comparator A

Treatment:

Biological: Trivalent influenza vaccine A

Trivalent influenza vaccine B

Active Comparator group

Description:

Active Comparator B

Treatment:

Biological: Trivalent influenza vaccine B